Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Press release for the Financial Results for the quarter and year ended 31 March, 2026.".
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences reported exceptional full-year FY26 results with revenue growing 29% to Rs 2,192 crore from Rs 1,695 crore in FY25. EBITDA surged 56% to Rs 661 crore with margins expanding from 25% to 30%. Net profit more than doubled, rising 109% to Rs 355 crore from Rs 170 crore, with PAT margin improving from 10% to 16%. Q4FY26 showed sequential improvement with revenue of Rs 602 crore, up 4% YoY. The company incurred capex of Rs 633 crore during FY26 to expand capabilities. Growth was driven by deeper engagement with large pharma customers, momentum in integrated discovery services, and investments in new modalities and next-generation technologies.
The results indicate strong operational execution and margin improvement, positioning the CRDMO favorably against peers. Doubling of net profit and significant capex deployment signal confidence in sustained growth, which could be positive for the stock given the strong fundamentals.